Edgewise Therapeutics has announced the start of an observational trial in participants with Becker Muscular Dystrophy (‘BMD’)) as assessed by functional measures and imagining endpoints. This global, multi-center trial is led by the GRASP (General Resolution and Assessments Solving Phenotypes) consortium and Virginia Commonwealth University (VCU), in collaboration with ImagingDMD University of Florida (UF).
The trial is expected to recruit approximately 150 individuals with BMD to collect information over a two-year period that may provide a more comprehensive understanding of the disease and help advance potential future therapies, like Edgewise’s lead clinical candidate, EDG-5506.
Read Edgewise’s FULL news release here.
Interesting further information
- Visit Duchenne explained to understand the terminology used when we talk about Duchenne research.
- Learn more about the science of Duchenne at one of 24 Science Education Programme workshops across the UK.
- Receive news and updates from Action Duchenne below;
WIN AN EASTER HAMPER!
